FindTrial
Sign In

Application Study of Intraoperative Contrast-enhanced Ultrasound Combined with Preoperative MRI in the Surgical Treatment of Liver Metastases from Colorectal Cancer

Long-Term Survival after Surgical Resection and Ablation Using Intraoperative Contrast-Enhanced Ultrasonography Combined with Preoperative MRI versus Preoperative MRI Alone for Colorectal Cancer Liver Metastases: A Multicenter, Prospective, Randomized Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060758
Enrollment
Unknown
Registered
2022-06-10
Start date
2022-06-20
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

control group:Preoperative MRI
experimental group:Preoperative MRI combined with intraoperative contrast-enhanced ultrasonography

Sponsors

Beijing Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Colorectal cancer liver metastases confirmed by pathology as colorectal adenocarcinoma; 2. Multiple liver metastases (<=10); 3. Good physical condition (ECOG score 0-1), able to tolerate liver metastases surgery; 4. Residual liver volume greater than 30% , with sufficient blood inflow and outflow, Child-Pugh A; 5. Initial or post-chemotherapy imaging assessment of liver metastases can be localized treated (resectable, or resectable combined with ablation), and achieving non evidence of disease (NED); 6. No extrahepatic metastases (excluding locally treatable lung metastases); 7. Blood test, liver and renal function parameters meet the indications for surgery.

Exclusion criteria

Exclusion criteria: 1. Unable to tolerate chemotherapy; 2. Insufficient residual liver volume after resection of liver metastases; 3. Non-radical surgery; 4. Unable to receive MRI or intraoperative contrast-enhanced ultrasonography for various reasons; 5. Concomitant or previous concomitant with other malignancies.

Design outcomes

Primary

MeasureTime frame
recurrence-free survival;—

Secondary

MeasureTime frame
recurrence rate;overall survival;—

Countries

China

Contacts

Public ContactBaocai Xing

Beijing Cancer Hospital

xingbaocai88@sina.com+86 13910721238

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026